Matthew Rosenblum
Written By: Julia Brabant, Updated September, 2026Five Years After Doctors Gave Him One to Three “Good Years,” Matthew Rosenblum Is a Husband and Father
Five years ago, Matthew Rosenblum had little reason to wonder whether he’d ever become a father.
At age 33 with Stage 4 pancreatic cancer that had already spread beyond his pancreas, he was facing a far more immediate question: How much time did he have left?
At the time, doctors estimated he might have one to three “good years,” and even that was if he was especially lucky.

Today, Matthew is almost five and a half years past his initial diagnosis. He’s also married, and he and his wife, Natalie, share a 1-year-old son, Asher. The couple married on Valentine’s Day 2025 after moving from Michigan to metro Atlanta, and in April, just days shy of Matthew’s four-year survival anniversary, they welcomed the son he once had little reason to believe he’d ever have.
The possibility of becoming a father had first come up years earlier under very different circumstances.
When Matthew’s first attempt at a Whipple procedure ended after surgeons discovered his cancer had spread too far to complete the operation, doctors asked whether he wanted to freeze his sperm. At the time, Matthew was still trying to wrap his brain around his own mortality, so whether he’d one day have children was among the least of his concerns.
“At this point, I didn’t think I could father my own children,” he said. “All of this was so foreign – I never really thought about my ability to have kids before; I just thought I would.”
Years later, with his cancer under control and the question still unresolved, Matthew found himself awake one night, doomscrolling in bed. He eventually Googled whether someone with his medical history might still be able to father a child and came across an article that suggested it was possible.
Within about 48 hours, Natalie shared that she was pregnant.
For someone once given little reason to plan ahead, life suddenly looked very different. Becoming a father also meant Matthew now had something new to lose.
“Will I die when my baby is young? I still think about that every day,” Matthew said. “I’m living as a miracle now, but the chance of my story ending like so many others is still very plausible.”
Matthew’s pancreatic cancer story began with symptoms that seemed strange for a man in his early 30s.
I woke up and found out I wasn’t dying, it was like emotional whiplash.
Testing initially revealed what doctors believed was a bile duct stricture, possibly autoimmune in nature given Matthew’s history of Crohn’s disease, which he learned he had at age 25. After additional testing suggested gallstones, doctors later removed his gallbladder. When symptoms returned, further testing finally revealed adenocarcinoma.
Doctors planned a Whipple procedure, but surgery revealed more extensive disease than expected. The tumor involved the head of Matthew’s pancreas, had invaded nearby structures and a major blood vessel, and had spread to several areas within the abdomen. Given the extent of the cancer, the operation was aborted.
Two weeks later, Matthew began FOLFIRINOX in hopes of shrinking the cancer enough to make surgery possible. Early scans showed slight improvement, but after eight cycles, imaging revealed progression in the pancreatic tumor and new liver metastases, forcing his medical team to change course.
Matthew’s pathogenic BRCA2 variant helped inform his medical team’s next treatment decision. Doctors switched him to a combination of gemcitabine, nab-paclitaxel, and cisplatin. Within two months, imaging showed that the liver metastases had improved or resolved. After several months of stable disease, his doctors began considering another surgical attempt, hoping a Whipple might now be possible.
This time, they completed it successfully.
“I woke up and found out I wasn’t dying,” Matthew said. “It was like emotional whiplash.”
Every scan Matthew has had since the summer of 2022 has been clear of recurrent cancer, though he’s had several scares. A lung nodule has since disappeared, while a concerning spot on his liver proved benign.
When you’re up, you’re up, and it’s great – and I’m up. Right now, things are good, and I’m going to ride this rail until I run out of track. I love the opportunities I’ve had and the life I’ve been able to lead, but I’m not so foolish as to think I know, with certainty, that this is over.
Initially, Matthew had scans every three months. Over time, he spaced them out to every four months. Now, he has them about once a year, with bloodwork in between.
His care team has also changed. After his original oncologist retired, Matthew saw another oncologist at Duke Cancer Institute for about a year. Once he and Natalie settled in Georgia, he moved his care closer to home at Emory University’s Winship Cancer Institute in Atlanta.
Matthew praises the care he received at Duke and appreciates that his new doctor takes his questions seriously and provides honest, thoughtful answers.
“I’m confident that if he can’t answer something, he’ll find someone who can,” Matthew said.
Having Asher has also changed the way Matthew thinks about another critical piece of his cancer story: genetics.
Matthew grew up in an Ashkenazi Jewish family, part of a population with elevated rates of several inherited genetic conditions as well as certain BRCA mutations.
Now, Matthew thinks about what his and Natalie’s genetic findings could mean for their son. Matthew carries a pathogenic BRCA2 variant as well as a BRCA1 variant of uncertain significance, or VUS – a genetic change for which there is not yet enough evidence to determine whether it is harmful. Natalie also has a BRCA2 VUS.
Because Matthew carries a pathogenic BRCA2 variant and Natalie is also of Ashkenazi Jewish heritage, genetic testing was particularly important as they thought about having children. His genetic counselor explained that if both parents carried pathogenic BRCA2 variants, a child could inherit one from each parent and develop BRCA2-related Fanconi anemia, a rare inherited disorder associated with bone marrow failure, developmental abnormalities and a high risk of childhood cancers.
Seeing a BRCA2 finding on Natalie’s genetic test was initially frightening, but her result was very different from Matthew’s. His BRCA2 variant is known to be pathogenic, while hers is a rare variant of uncertain significance, or VUS, meaning there is not enough evidence to determine whether it is harmful or benign.
The uncertainty mattered because Fanconi anemia can occur when a child inherits disease-causing BRCA2 variants from both parents. Each child has a 50% chance of inheriting Matthew’s variant and a 50% chance of inheriting Natalie’s, as well as a 25% chance of inheriting both. But because Natalie’s rare variant has not been shown to be conclusively disease-causing, doctors could not determine whether inheriting both would cause Fanconi anemia. After consulting several geneticists, they concluded there was simply not enough data to estimate the baby’s risk.
Thankfully, Asher was born healthy, but longer-term genetic questions remain. Asher is still very young, so they don’t yet know which, if any, of his parents’ genetic variants he inherited. As he grows, Matthew wants him to have accurate information and a full understanding of any health risks he may face.
Matthew also wishes this kind of information were easier for more families to find. He believes communities with elevated BRCA rates need clearer, more relevant resources about hereditary cancer risks and what they may mean for their health. He is especially frustrated by the disproportionate focus on breast and ovarian cancer in discussions of BRCA.
That emphasis can reinforce the idea that BRCA is primarily a women’s issue. Matthew sees this within Ashkenazi Jewish communities, where decades of screening, counseling, and education have created broad familiarity with hereditary disease, but not always with the full range of cancers associated with BRCA1 and BRCA2.
There’s a spectrum of support needed for survivors of pancreatic cancer. You’re basically told, if you survive, you’re really lucky, and you can figure out the rest later. The lack of a supportive landing after treatment is really jarring.
“I routinely meet people in my community who are very familiar with BRCA but still have an incomplete or outdated understanding of the cancers associated with it,” he said. “I’m often surprised by how many people know about the connection to breast and ovarian cancer but are unaware that BRCA1 and BRCA2 can also be associated with pancreatic cancer.”
These questions have held Matthew’s attention for years. With an academic background in Jewish social science, he once expected a career in research and teaching. Since his diagnosis, he has drawn on those interests to speak and write about BRCA2, pancreatic cancer, Jewish heritage and identity.
He continues to share his story through the Seena Magowitz Foundation, other pancreatic cancer groups, and occasional podcast and video appearances. He also raises awareness about hereditary cancer and men’s health through Facing Our Risk of Cancer Empowered (FORCE).
Living long enough to raise those questions has also introduced Matthew to a side of pancreatic cancer he believes receives far too little attention: what happens when treatment actually works.
“There’s a spectrum of support needed for survivors of pancreatic cancer,” Matthew said. “You’re basically told, if you survive, you’re really lucky, and you can figure out the rest later. The lack of a supportive landing after treatment is really jarring.”
Matthew speaks openly about the challenges of surviving cancer at a young age, including the lasting psychological, financial and physical effects. For him, even lingering “chemo brain” has taken on a new dimension alongside the sleep deprivation of raising a toddler
When asked what he would tell the version of himself who woke up from the aborted Whipple believing he was going to die, Matthew’s answer was immediate.
“First and foremost, I’d tell myself to get a therapist immediately.” He wishes he had taken his mental health more seriously and encourages patients and survivors, especially those diagnosed young, to seek out support.
For all the ways cancer continues to influence his life, Matthew doesn’t find discussing it especially difficult.
“I have no problem talking about cancer; I don’t feel weird about it,” Matthew said. “You’re traumatized for a while, but if you live through it, it becomes something you get to laugh about. It doesn’t really sadden me to think about anymore. I worry about the future.”
However, almost five and a half years after his diagnosis, Matthew has plenty of reasons to laugh, celebrate and plan for the future.
He’s also learned to embrace where he is now without needing certainty about what comes next.
“When you’re up, you’re up, and it’s great – and I’m up,” Matthew said. “But you can be down just as easily, and the floor, in this case, can be way down. Right now, things are good, and I’m going to ride this rail until I run out of track. I love the opportunities I’ve had and the life I’ve been able to lead, but I’m not so foolish as to think I know, with certainty, that this is over.”
For now, Matthew, Natalie, and Asher live in Decatur, GA, with their 10-year-old pug, Monique. Matthew works in the professional development department of an engineering society. When he isn’t chasing the baby around, he’s an avid New York Knicks and University of Kentucky basketball fan who also collects coins and rare books
MORE WARRIOR STORIES
Tom Arai
Initially Diagnosed With Stage 4 Pancreatic Cancer, 10 Years Later, He Helps Other Survivors.
Dave Glick
Against All Odds, Dave Glick Triumphed Over Colon, Pancreas & Prostate Cancer
Nancy Pollack
Diagnosed With Inoperable Stage 3 Pancreatic Cancer at 80, Nancy Prioritizes Life Beyond Treatment